Nature Reviews Cancer contents November 2015 Volume 15 Number 11 pp635-694

If you are unable to see the message below, click here to view.

Advertisement
New! First CRISPR/Cas9 antibody validated for chromatin immunoprecipitation A new addition to Diagenode's Cas9 collection! Recognizes the C-terminus of the Cas9 nuclease Ideal for fusion protein experiments Validated in IP, WB and IF  Learn more and get best quality data
TABLE OF CONTENTS
November 2015 Volume 15 Number 11		Advertisement
Impact Factor 37.912 *	In this issue Research Highlights Reviews Perspectives Also this month Article series: Cancer origins  Featured article: Centrosomes and cancer: revisiting a long-standing relationship Pierre Gönczy	Determine the Metabolic Phenotype of Your Cells The XFp Cell Energy Phenotype Test Kit from Seahorse Bioscience. Using as few as 15,000 cell and the XFp Analyzer, the XF Cell Energy Phenotype Test identifies your cells' metabolic phenotype as well as their metabolic potential - the relative utilization of mitochondrial respiration and glycolysis.  http://bit.ly/1Caw9Eq
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Collaborative diagnostic assay development & validation Co-develop your RNA, DNA or protein based diagnostics (ideally in oncology, infectious diseases & pharmacogenomics) or enabling technologies. MRCT is a life science medial research charity committed to improving the odds for patients. Click to learn more
Advertisement
The Naturejobs Career Expo is coming to Düsseldorf for the first time on 26 November! This career fair offers young, talented researchers an excellent opportunity to meet a diverse selection of national and international employers from academic institutions and scientific industries. The event is free and offers you a chance to meet and network with employers and leading scientific institutions and attend useful workshops.  Register and find out more.
RESEARCH HIGHLIGHTS Top Therapeutic resistance: Multiple mechanisms to keep going p635 | doi:10.1038/nrc4034 Roger Lo and colleagues characterized the melanoma genome, transcriptome and epigenome to understand the landscape of acquired resistance to MAPK pathway inhibitors. PDF Glioma: Repurposed drugs combined to amplify autophagy p636 | doi:10.1038/nrc4033 A study published in Cancer Cell reports that two FDA-approved drugs — an antidepressant and an anticoagulant — synergize to promote autophagy and slow glioma progression in mice. PDF Metabolism: MYC clocks on p636 | doi:10.1038/nrc4036 Chi Dang and colleagues show that MYC is involved in the regulation of the circadian clock, and its deregulated expression in cancer cells leads to a loss of cellular circadian rhythm and impacts cell metabolism. PDF Epigenetics: Place your BETs p638 | doi:10.1038/nrc4035 Three papers have reported new data on resistance to bromodomain and extraterminal (BET) inhibitors and how best to use these inhibitors in combination therapy. PDF IN BRIEF Leukaemia: The part played by pathogens in pB-ALL | Oncogenes: A new start for ALK transcription | Melanoma: Dual effects of PD1 blockade | Tumour evolution: Genetic and epigenetic co-dependency PDF Cancer JOBS of the week Postdoctoral Associate in Cancer Genomics and Personalized Medicine University of North Carolina at Chapel Hill Cancer Research UK 4 Year PhD Studentships 2016 Cancer Research UK Manchester Institute Senior Clinical Lecturer in Cancer & Inflammation Queen Mary University of London Three Year Postdoctoral Position - Epigenetic Mechanisms in Cancer Centre Léon Bérard Assistant, Associate, or Full Professor at the Yale Cancer Biology Institute Yale Cancer Biology Institute More Science jobs from Cancer EVENT Nuclear Reprogramming and the Cancer Genome 2016 21.02.16 La Jolla, CA More science events from
Advertisement
Studying DNA methylation has never been simpler!  Diagenode provides a full suite of products dedicated to epigenetics research. Our innovative DNA methylation product line includes: Trusted antibodies — plus 5-mc 33D3 antibody Reliable and robust kits for magnetic MeDIP and hMeDIP New! Lowest cost and highest quality RRBS kit Learn more.
REVIEWS		Top
Centrosomes and cancer: revisiting a long-standing relationship Pierre Gönczy p639 | doi:10.1038/nrc3995 This Review discusses recent advances that shed new light on the relationship between centrosomes and cancer, raising the possibility that centrosome aberrations contribute to this disease in different ways than initially envisaged. Abstract | Full Text | PDF
Article series: Cancer origins Functional and genetic deconstruction of the cellular origin in liver cancer Jens U. Marquardt, Jesper B. Andersen & Snorri S. Thorgeirsson p653 | doi:10.1038/nrc4017 Liver tumorigenesis is complex and depends on the cellular origin of a tumour as well as on environmental influences. This Review discusses the origins of various primary liver cancers, integrating our current understanding of cells of origin, liver tumour genomics and the disrupted hepatic microenvironment. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer David D. Bowtell, Steffen Böhm, Ahmed A. Ahmed, Paul-Joseph Aspuria, Robert C. Bast, Jr, Valerie Beral, Jonathan S. Berek, Michael J. Birrer, Sarah Blagden, Michael A. Bookman, James D. Brenton, Katherine B. Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David G. Huntsman, Marcin Iwanicki, Beth Y. Karlan, Allyson Kaye, Ernst Lengyel, Douglas A. Levine, Karen H. Lu, Iain A. McNeish, Usha Menon, Steven A. Narod, Brad H. Nelson, Kenneth P. Nephew, Paul Pharoah, Daniel J. Powell, Jr, Pilar Ramos, Iris L. Romero, Clare L. Scott, Anil K. Sood, Euan A. Stronach & Frances R. Balkwill p668 | doi:10.1038/nrc4019 This Opinion article outlines a set of research priorities, based on discussions held at the 2015 Helene Harris Memorial Trust Ovarian Cancer Action meeting, that the authors believe will reduce incidence and improve outcomes for women with high-grade serous ovarian cancer. Abstract | Full Text | PDF | Supplementary information
OPINION The mini-driver model of polygenic cancer evolution Francesc Castro-Giner, Peter Ratcliffe & Ian Tomlinson p680 | doi:10.1038/nrc3999 Most cancer genomics studies have focused on identifying the most important somatic mutations ('major drivers') that promote tumour growth. However, many cancer-associated mutations might instead have relatively weak tumour-promoting effects. This Opinion article highlights the existence of these mutations (termed 'mini drivers') and the functional effects that they might have. Abstract | Full Text | PDF
OPINION Directly targeting transcriptional dysregulation in cancer Thomas J. Gonda & Robert G. Ramsay p686 | doi:10.1038/nrc4018 What is the best approach to avoid resistance to therapies that target intracellular signalling pathways? In this Opinion article, Gonda and Ramsay argue that increased effort should be made to target transcriptional regulators directly. Abstract | Full Text | PDF
Corrigendum: Hypermutation in human cancer genomes: footprints and mechanisms Steven A. Roberts & Dmitry A. Gordenin p694 | doi:10.1038/nrc4028 Full Text | PDF
Advertisement
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. Now open for submissions: http://bit.ly/1xXPzzM
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.